Cyt387 - CAS 1056634-68-4
Catalog number: B0084-307720
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Cyt387, also called Momelotinib, under the IUPAC name N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, is an ATP competitive inhibitor of JAK1 (IC50 = 11 nM) and JAK2 (IC50 = 18 nM) with potential antineoplastic activity, which may result in the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells.
Publictions citing BOC Sciences Products
  • >> More
Solid powder
N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide; CYT 387; CYT-387; CYT387; Momelotinib; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; Cyt387; 1056634-68-4; MOMELOTINIB; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; Cyt-387; CYT 387; UNII-6O01GMS00P; CHEMBL1078178; C23H22N6O2; CYT 11387; Momelotinib (CYT387); N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; CYT 11387, Cyt-387, 1056634-68-4; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; Cyt387, CYT 11387, Cyt-387; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(Cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide; N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide; Momelotinib [USAN]; S2219_Selleck; Momelotinib (USAN/INN); MLS006011154; 6O01GMS00P; GTPL7791; SCHEMBL2237234; CTK8C0828; AOB4616; CYT387/CYT-387 QCR-259; SYN1035; HMS3244K19; HMS3244K20; HMS3244L19; CYT387, CYT11387; CYT387,CYT 11387; ABP000831; AN-507; ANW-65331; BDBM50311017; CYT-11387; RS0045; ZINC43199890; AKOS015904624; Cyt387-Supplied by Selleck Chemicals; BCP9000570; CS-0053; GS-0387; LS41099; NCGC00244257-01; 4CA-0426; AK102858; HE067505; HY-10961; KB-76370; SMR004702928; AB003377; AJ-108274; TC-154076; ST24048452; X7506; D10315; W-5616; BRD-K87737963-001-01-1; I14-17003; N-(cyanomethyl)-4-[2-(4-morpholinoanilino)pyrimidin-4-yl]benzamide; N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide; Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-; 1160597-06-7
Soluble in DMSO
Store at -20° C
An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity (IC50s = 11 and 18 nM, respectively)
Quality Standard:
In-house standard
1.292 g/cm3
Canonical SMILES:
1.New Drugs for the Treatment of Myelofibrosis
Ruben A. Mesa. Curr Hematol Malig Rep (2010) 5:15–21
Various therapeutic strategies are being developed to try to block the proliferative stimulus associated with these MPNassociated mutations. Current testing using these inhibitors can be divided into three groups: preclinical testing (based on in vitro activity against cells containing JAK2V617F), ongoing testing in murine models, and testing in clinical trials. Between 10 and 20 agents with reported in vitro or murine-model activity are in the pipeline (Fig. 1), but we will focus on those agents in which clinical activity has already been reported in the public forum. JAK2 inhibition clinical results can be divided into two categories of agents: novel small molecules designed and tested for specificity and selectivity against JAK2 (INCB018424, XL019, TG101348, SB1518, CYT387), and agents that inhibit a variety of kinases including JAK2 (ITF2357, CEP-701).
2.The New Landscape of Therapy for Myelofibrosis
Krisstina Gowin & Robyn Emanuel & Holly Geyer & Ruben A. Mesa. Curr Hematol Malig Rep (2013) 8:325–332
CYT387 (momelotinib), a JAK2 and JAK1 inhibitor, has recently completed phase II testing and demonstrated significant efficacy in improving anemia and transfusion dependence, as well as splenomegaly and constitutional symptoms in MF patients. Dose-limiting toxicities, including elevation in lipase levels and neurological effects, continue to be investigated. Several other JAK2 inhibitors are currently undergoing clinical testing with limited data in the public domain. These include LY2784544, NS018 and BMS-911543. The results of these phase I–II studies are anticipated with great interest. Three JAK2 inhibitors have ceased further development for MF, including XL019, which was tested in 2007 and 2008 but not pursued as a result of neurologic toxicities. Similarly, testing for CEP701 and AZD1480 was halted for a variety of reasons including lack of efficacy.
3.Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary
Stefan Schmidt. memo (2013) 6:181–184
CYT387 is a JAK-1 and JAK-2 inhibitor and was investigated in a phase I/II clinical trial in MF. Updated data presented by Pardanani et al. showed that cohorts treated with 150 mg QD (N = 52), 300 mg QD (N = 60), 150 mg BID (N = 42) achieved an overall mean decrease in spleen volume of 38 % (36–46 %), which was reached after a median of 22 days of treatment and maintained for 744 days (median). A total of 68 % patients became transfusion independent of which 50 % maintained transfusion independence for at least 1 year. In addition, an increase of hemoglobin levels of at least 2 g/dL was achieved in 13 % of patients. CYT387 treated patients showed a marked improvement of constitutional symptoms after 6 months of treatment. Among the observed hematologic AEs, thrombocytopenia was most frequent constituting 22 % and 24 % of grade 1/2 and grade 3/4 AEs, respectively. Nonhematologic AEs grade 3/4 were observed in only 1 % (headache). Similarly infrequent and second most severe were diarrhea (4 %), peripheral neuropathy (2 %), and dizziness (1 %) all of which were rated grade 2. Given the efficacy in reducing spleen volume and constitutional symptoms this substance could become of particular clinical interest because of the additionally observed transfusion independence, which might significantly contribute to a further increase in quality of life (QoL).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products

CAS 1092939-17-7 Ruxolitinib phosphate

Ruxolitinib phosphate
(CAS: 1092939-17-7)

Ruxolitinib phosphate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus J...

CAS 1092578-47-6 (3S,4S)-Tofacitinib

(CAS: 1092578-47-6)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

(CAS: 1334298-90-6)

Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...

CAS 945755-56-6 XL019

(CAS: 945755-56-6)

NS-018 hydrochloride
(CAS: 1239358-85-0)

The hydrochloride salt form of NS-018 which is a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tum...

CAS 944842-54-0 Decernotinib

(CAS: 944842-54-0)

Decernotinib, also known as VX-509 or VRT-831509 or adelatinib, is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. VX-509 may repr...

CAS 1206163-45-2 Solcitinib

(CAS: 1206163-45-2)

Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis, systemic ...

(CAS: 1262832-74-5)

PF-956980, a close analogue of Tofacitinib, is a JAK3-selective inhibitor used as an anti-inflammatory agent. Besides, some studies showed that PF-956980 striki...

CAS 1204918-72-8 SB1317

(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

CAS 1056636-07-7 CYT387 Mesylate

CYT387 Mesylate
(CAS: 1056636-07-7)

CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 937272-79-2 Pacritinib

(CAS: 937272-79-2)

Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic acti...

CAS 1450881-55-6 SAR-20347

(CAS: 1450881-55-6)

SAR-20347 is a small molecule inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively. SAR-20347 dose dependently (1 nM-10 μM) ...

CAS 1271022-90-2 BMS-911543

(CAS: 1271022-90-2)

BMS-911543 is an orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS-...

CAS 1092939-16-6 Ruxolitinib sulfate

Ruxolitinib sulfate
(CAS: 1092939-16-6)

Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1...

CAS 857064-38-1 WP1066

(CAS: 857064-38-1)

WP1066 is a Stat3 inhibitor and JAK2 inhibitor. WP1066 is also a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells a...

CAS 1257704-57-6 CEP33779

(CAS: 1257704-57-6)

CEP-33779 is a highly selective, orally active, small-molecule inhibitor of JAK2. CEP-33779 induced regression of established colorectal tumors, reduced angioge...

CAS 1206161-97-8 Filgotinib

(CAS: 1206161-97-8)

Filgotinib, also known as GLPG0634, is a potent and selective JAK1 inhibitor. Filgotinib displayed a selectivity of 30-fold for JAK1- over JAK2-dependent signal...

(CAS: 1310726-60-3)

Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on...

CAS 1229236-86-5 LY2784544

(CAS: 1229236-86-5)

Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...

CAS 273727-89-2 ZM 39923

ZM 39923
(CAS: 273727-89-2)

ZM 39923 inhibits Janus kinase (IC50=10 nM).

Chemical Structure

CAS 1056634-68-4 Cyt387

Quick Inquiry

Verification code

Featured Items